- Oncolines is a CRO that offers precision medicine services in the fields of oncology and immunotherapy
- Keensight Capital initially acquired Symeres in 2021
- Oncolines is Symeres’ third acquisition in the past 10 months
Keensight Capital’s portfolio company Symeres has acquired Oncolines, a contract research organisation (CRO) that provides early biology services and cell-line profiling assays. Oncolines is Symeres’ third acquisition in the past 10 months and will take group revenues to over €100 million.
Based in Oss in the Netherlands, Oncolines is a CRO that offers precision medicine services in the fields of oncology and immunotherapy. The company’s clients are clinical and pre-clinical biopharma customers that seek to differentiate their drug candidates.
The acquisition complements Symeres’ drug discovery capabilities with biology and biophysics capabilities in oncology, according to Keensight.
“We are pleased to support Symeres in the acquisition of Oncolines,” said Amit Karna, partner at Keensight Capital. “We are convinced of the strategic, geographic, and cultural fit of the combination, and the complementarity of Oncolines’ capabilities in oncology-focused in-vitro pharmacology.”
Paris-based Keensight Capital is a European growth buyout firm that targets companies with revenues in the range of €10 million to €400 million.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: 
